×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Company: JAK Inhibitors in Parkinson's Disease
company
1,004 words
KG: JAK
2026-03-28
section:companies
kind:company
state:published
topic:parkinsons
topic:neuroinflammation
topic:jak-stat
Contents
JAK Inhibitors in Parkinson's Disease
Knowledge Graph
Related Hypotheses (20)
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.42
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Epigenetic Memory Erasure via TET2 Activation
Score: 0.52
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.44
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
VCP-Mediated Autophagy Enhancement
Score: 0.41
Temporal TET2-Mediated Hydroxymethylation Cycling
Score: 0.41
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.40
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.39
Show 15 more
Related Analyses (14)
Synaptic pruning by microglia in early AD
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 9 more
Related Experiments (30)
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
See Also (5)
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: regulates
Packard Center for ALS Research
institution · KG edge: activates
AKT1 Gene
gene · KG edge: interacts_with
ABCG2 (BCRP) - ATP Binding Cassette Subfamily G Member
gene · KG edge: therapeutic_target
ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member
gene · KG edge: therapeutic_target
Knowledge Graph (12 edges)
JAK
co_discussed
STAT3
JAK
co_discussed
STING
JAK
co_discussed
T CELL
JAK
co_discussed
T CELLS
JAK
co_discussed
JNK
JAK
co_discussed
MTOR
JAK
associated_with
STAT3
JAK
interacts_with
TLR
JAK
interacts_with
PI3K
JAK
interacts_with
AKT